학술논문
Associations of presenting visual acuity with morphological changes on OCT in neovascular age-related macular degeneration: PRECISE Study Report 2.
Document Type
Academic Journal
Author
Chandra S; National Institute of Health Research Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, UK.; Institute of Ophthalmology, University College, London, UK.; Gurudas S; Institute of Ophthalmology, University College, London, UK.; Burton BJL; James Paget University Hospitals NHS Foundation Trust, Norfolk, UK.; Menon G; Frimley Health NHS Foundation Trust, Surrey, UK.; Pearce I; The Royal Liverpool and Broadgreen University Hospitals NHS Foundation Trust, Liverpool, UK.; Mckibbin M; Leeds Teaching Hospitals NHS Trust, Leeds, UK.; Kotagiri A; South Tyneside and Sunderland NHS Foundation Trust, Sunderland, UK.; Talks J; Newcastle Hospitals NHS Foundation Trust, Newcastle, UK.; Grabowska A; King's College Hospital NHS Foundation Trust, London, UK.; Ghanchi F; Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK.; Gale R; Hull York Medical School and York, University of York and Scarborough Teaching Hospital NHS Foundation Trust, York, UK.; Giani A; Boehringer Ingelheim, Binger Str. 173, 55216, Ingelheim am, Rhein, Germany.; Chong V; Institute of Ophthalmology, University College, London, UK.; Yamaguchi TCN; Boehringer Ingelheim, Binger Str. 173, 55216, Ingelheim am, Rhein, Germany.; Pal B; National Institute of Health Research Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, UK.; Thottarath S; National Institute of Health Research Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, UK.; Pakeer RM; National Institute of Health Research Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, UK.; Chandak S; National Institute of Health Research Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, UK.; Montesel A; National Institute of Health Research Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, UK.; Sivaprasad S; National Institute of Health Research Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, UK. sobha.sivaprasad@nhs.net.; Institute of Ophthalmology, University College, London, UK. sobha.sivaprasad@nhs.net.
Source
Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8703986 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5454 (Electronic) Linking ISSN: 0950222X NLM ISO Abbreviation: Eye (Lond) Subsets: MEDLINE
Subject
Language
English
Abstract
Purpose: To study associations of optical coherence tomography (OCT) features with presenting visual acuity (VA) in treatment naive neovascular age-related macular degeneration (nAMD).
Methods: Patients with nAMD initiated on aflibercept therapy were recruited from December 2019 to August 2021. Demographic and OCT (Spectralis, Heidelberg Engineering) features associated with good VA (VA ≥ 68 ETDRS letters, Snellen ≥ 6/12) and poor VA (VA < 54 letters, Snellen < 6/18) were analysed using Generalised Estimating Equations to account for inter-eye correlation.
Results: Of 2274 eyes of 2128 patients enrolled, 2039 eyes of 1901 patients with complete data were analysed. Mean age was 79.4 (SD 7.8) years, female:male 3:2 and mean VA 58.0 (SD 14.5) letters. On multivariable analysis VA < 54 letters was associated with increased central subfield thickness (CST) (OR 1.40 per 100 µm; P < 0.001), foveal intraretinal fluid (OR 2.14; P < 0.001), polypoidal vasculopathy (PCV) relative to Type 1 macular neovascularisation (MNV) (OR 1.66; P = 0.049), presence of foveal subretinal hyperreflective material (SHRM) (OR 1.73; P = 0.002), foveal fibrosis (OR 3.85; P < 0.001), foveal atrophy (OR 5.54; P < 0.001), loss of integrity of the foveal ellipsoid zone (EZ) or external limiting membrane (ELM) relative to their preservation (OR 3.83; P < 0.001) and absence of subretinal drusenoid deposits (SDD) (presence vs absence; OR 0.75; P = 0.04). These features were associated with reduced odds of VA ≥ 68 letters except MNV subtypes and SDD.
Conclusion: Presence of baseline fovea-involving atrophy, fibrosis, intraretinal fluid, SHRM, PCV EZ/ELM loss and increased CST determine poor presenting VA. This highlights the need for early detection and treatment prior to structural changes that worsen baseline VA.
(© 2023. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.)
Methods: Patients with nAMD initiated on aflibercept therapy were recruited from December 2019 to August 2021. Demographic and OCT (Spectralis, Heidelberg Engineering) features associated with good VA (VA ≥ 68 ETDRS letters, Snellen ≥ 6/12) and poor VA (VA < 54 letters, Snellen < 6/18) were analysed using Generalised Estimating Equations to account for inter-eye correlation.
Results: Of 2274 eyes of 2128 patients enrolled, 2039 eyes of 1901 patients with complete data were analysed. Mean age was 79.4 (SD 7.8) years, female:male 3:2 and mean VA 58.0 (SD 14.5) letters. On multivariable analysis VA < 54 letters was associated with increased central subfield thickness (CST) (OR 1.40 per 100 µm; P < 0.001), foveal intraretinal fluid (OR 2.14; P < 0.001), polypoidal vasculopathy (PCV) relative to Type 1 macular neovascularisation (MNV) (OR 1.66; P = 0.049), presence of foveal subretinal hyperreflective material (SHRM) (OR 1.73; P = 0.002), foveal fibrosis (OR 3.85; P < 0.001), foveal atrophy (OR 5.54; P < 0.001), loss of integrity of the foveal ellipsoid zone (EZ) or external limiting membrane (ELM) relative to their preservation (OR 3.83; P < 0.001) and absence of subretinal drusenoid deposits (SDD) (presence vs absence; OR 0.75; P = 0.04). These features were associated with reduced odds of VA ≥ 68 letters except MNV subtypes and SDD.
Conclusion: Presence of baseline fovea-involving atrophy, fibrosis, intraretinal fluid, SHRM, PCV EZ/ELM loss and increased CST determine poor presenting VA. This highlights the need for early detection and treatment prior to structural changes that worsen baseline VA.
(© 2023. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.)